

Cytos Biotechnology Ltd holds a Bondholders' meeting today. Trading of Cytos shares and convertible bonds temporarily suspended.

Schlieren (Zurich), Switzerland, November 10, 2011, – Cytos Biotechnology Ltd (SIX:“CYTN”; the “Company”) holds, as previously announced, today a meeting of the Bondholders in order to vote on the restructuring proposal for the convertible bonds. As the outcome of the meeting is not known and such outcome may be price sensitive, Cytos has applied with the SIX Swiss Exchange to suspend trading of Cytos' shares as well as Cytos' convertible bonds from the start of today's trading session until at least one hour after the outcome of the meeting has been communicated by Cytos in a media release. The SIX Swiss Exchange has approved this request.

By doing this, Cytos intends to provide equal treatment of all shareholders and bondholders with respect as to their ability to trade their Cytos securities.

For further information please contact:

Cytos Biotechnology Ltd

Harry Welten

Chief Financial Officer

Tel.: +41 44 733 46 46

e-Mail: harry.welten@cytos.com

Website: www.cytos.com

About Cytos Biotechnology Ltd

Cytos Biotechnology Ltd is a Swiss public biotechnology company that specializes in the discovery, development and commercialization of a new class of biopharmaceutical products – the Immunodrugs™. Immunodrugs™ are intended for use in the treatment and prevention of common chronic diseases, which afflict millions of people worldwide. Immunodrugs™ are designed to instruct the patient's immune system to produce desired therapeutic antibody or T cell responses that modulate chronic disease processes. The Immunodrug™ candidates are developed both in-house and together with Novartis, Pfizer and Pfizer Animal Health. Founded in 1995 as a spinoff from the Swiss Federal Institute of Technology (ETH) in Zurich, the Company is located in Schlieren (Zurich). Cytos Biotechnology Ltd is listed on the main segment at the SIX Swiss Exchange (SIX:“CYTN”).

This foregoing press release may contain forward-looking statements that include words or phrases such as “are intended for”, “are designed to”, or other similar expressions. These forward-looking statements are subject to a variety of significant uncertainties, including scientific, business, economic and financial factors, and therefore actual results may differ significantly from those presented. There can be no assurance that any further therapeutic entities will enter clinical trials, that clinical trial results will be predictive for future results, that therapeutic entities will be the subject of filings for regulatory approval, that any drug candidates will receive marketing approval from the U.S. Food and Drug Administration or equivalent regulatory authorities, or that drugs will be marketed successfully. Against the background of these uncertainties readers should not rely on forward-looking statements. The company assumes no responsibility to update forward-looking statements or adapt them to future events or developments. This document does not constitute an offer or invitation to subscribe or purchase any securities of Cytos Biotechnology Ltd.